Journal article

Development and Clinical Applications of Novel Oral Anticoagulants. Part I. Clinically Approved Drugs

Ingo Ahrens, Karlheinz Peter, Gregory YH Lip, Christoph Bode

DISCOVERY MEDICINE | DISCOVERY MEDICINE | Published : 2012

Abstract

Two new classes of orally available anticoagulant drugs, the direct thrombin inhibitor (dabigatran etexilate) and direct factor Xa inhibitors (the -xabans), have been approved for various clinical indications, as alternatives to the vitamin K antagonists (e.g., warfarin). These include the prevention of venous thromboembolism after major orthopedic surgery, the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, and the secondary prevention and treatment of venous thromboembolism including pulmonary embolism. Other clinical indications including the add-on therapy to dual antiplatelet therapy in patients with acute coronary syndrome and extended prophylaxis of ven..

View full abstract